Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Undertreatment of Newly-Diagnosed MM Evaluated

Clin Lymphoma Myeloma Leuk; ePub 2018 Feb 3; Fakhri, et al

Certain age, health status, race, and socioeconomic factors appear to be linked with receiving no treatment for multiple myeloma (MM), according to a study involving nearly 4,200 individuals. Participants were from the 2007-2011 SEER-Medicare database and had plasma cell myeloma. Investigators looked at factors linked with receiving no treatment for MM. Among the results:

  • 373 had no claims showing MM treatment nor ICD-9 codes for MM-defining clinical features.
  • Of ~3,800 patients with active MM, 4 in every 10 had no claims for systemic treatment.
  • Patients who were older, had poor performance indicators, and had comorbidities were more likely to receive no systemic treatment.
  • The same was true for blacks, those with lower socioeconomic status, and patients receiving Medicaid.

Citation:

Fakhri B, Fiala M, Tuchman S, Wildes T. Undertreatment of older patients with newly diagnosed multiple myeloma in the era of novel therapies. [Published online ahead of print February 3, 2018]. Clin Lymphoma Myeloma Leuk. doi: 10.1016/j.clml.2018.01.005.